Floatz logo

Nilutamide

Hypogonadism

SWOG Cancer Research NetworkSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Hypogonadism cohort.

Asset / SponsorPhaseRating
Carboplatin
University of Washington
Phase 2BB
Testosterone Undecylate
Royal College of Surgeons, Ireland
Phase 3BB
Prednisone
SWOG Cancer Research Network
Phase 3BB
Docetaxel
SWOG Cancer Research Network
Phase 3BB
Abiraterone
SWOG Cancer Research Network
Phase 3BB

View all 35 →

Same molecule, other indications

Nilutamide is also rated in:

prostate adenocarcinomaActive
BB
Indicative · Phase 3
70 / 100
View asset →
prostate cancerActive
BB
Indicative · Phase 3
67 / 100
View asset →
prostate carcinomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →